Scienture partners with distributor to sell REZENOPY naloxone spray to 2,000 US opioid treatment clinics

Bitget2026/09/22 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Scienture Holdings entered an exclusive sales, marketing, distribution deal for REZENOPY naloxone spray with a partner focused on addiction treatment centers.
Deal creates a dedicated channel across about 2,000 U.S. opioid treatment program clinics and other addiction treatment networks.
Scienture continues selling REZENOPY outside this segment through wholesalers, GPOs, other distributors, institutional customers.
IQVIA data for MAT July 2026 shows the U.S. naloxone market at about USD 140 million annual sales across 9,800,000 units.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220815PRIMZONEFULLFEED9830920) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Scienture partners with distributor to sell REZENOPY naloxone spray to 2,000 US opioid treatment clinics

You may also like

Crypto prices